PTGX
Protagonist Therapeutics, Inc
stockNASDAQ
protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 142.44 | 2026-09-28 | -1.34% | 1.144 |
| 1M | 145.72 | 2026-09-04 | -3.56% | 1.466 |
| 3M | 131.50 | 2026-07-06 | +6.87% | 0.639 |
| 6M | 102.89 | 2026-04-06 | +36.58% | 0.736 |
| 1Y | 64.83 | 2025-10-03 | +116.77% | 0.200 |
| 2Y | 44.37 | 2024-10-04 | +216.72% | — |
| 5Y | 17.75 | 2021-10-04 | +691.72% | 0.909 |
Protagonist Therapeutics, Inc (NASDAQ:PTGX) stock price today is $140.53, and today's volume is 760,304. PTGX is up 0.963% today. The 30 day average volume is 649,865. PTGX market cap is $9.09B with 64.71M shares outstanding.